| Patient | Benny Leonard |
|---|---|
| Date of birth | 1896-04-07 |
| Identifiers | MRN HR-BX008-SYN-TD; SSN (made up) 000-08-4106 |
| Document date | 1946-05-26 |
| Author | Miriam Okafor-Rosenthal, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review on the day of the cardiology consultation. [S]
Mr. Leonard returns two weeks after intake and was seen this morning by Dr. Achebe-Lindqvist of cardiology, who did an echocardiogram, an exercise stress echocardiogram and a coronary calcium scan. The echocardiogram showed thickening of the heart muscle from high blood pressure with a normal pumping function, and the stress test showed no sign of narrowed arteries; his breathlessness at peak exercise came with a very high blood pressure rise. The calcium score was 186. He has taken losartan-hydrochlorothiazide each morning, and his home readings over the past week averaged 146/92 mmHg. He has refereed only short undercards, as advised, and has had no chest tightness on those nights. He is relieved that his license is not at risk and worried about the cost of another medicine. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 146/92 mmHg over seven days |
| Echocardiogram | Concentric hypertrophy, septum 13 mm, mass index 118 g/m2, ejection fraction 62% |
| Stress echocardiogram | About 10.5 METs; no ischemia; peak blood pressure 226/98 mmHg |
| Coronary calcium score | Agatston 186, about the 80th percentile |
| Kidney function | Creatinine 1.04 mg/dL, potassium 4.0 mmol/L two weeks after starting treatment |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest tightness on undercard nights; no palpitations, fainting, orthopnea or ankle swelling |
| Respiratory | Positive | Breathless only at peak effort on the treadmill this morning |
| Constitutional | Negative | No lightheadedness or tiredness on the new tablet |
| Psychiatric | Positive | Worry about money and work, less than at intake |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning | One tablet each morning | Oral route | 1946-05-12 to 1946-06-30 | completed | S |
| Atorvastatin 40 mg tablet, one each evening | One tablet each evening | Oral route | 1946-05-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1946-05-26 | Body height | 165 | cm | S |
| 1946-05-26 | Body weight | 74.4 | kg | S |
| 1946-05-26 | Body mass index (BMI) [Ratio] | 27.3 | kg/m2 | S |
| 1946-05-26 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1946-05-26 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 1946-05-26 | Heart rate | 74 | /min | S |
| 1946-05-26 | Respiratory rate | 16 | /min | S |
| 1946-05-26 | Body temperature | 36.6 | Cel | S |
| 1946-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1946-05-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-146 mmol/L | Normal | S |
| 1946-05-26 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.3 mmol/L | Normal | S |
| 1946-05-26 | Urea nitrogen [Mass/volume] in Serum or Plasma | 16 | mg/dL | 7-25 mg/dL | Normal | S |
| 1946-05-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1946-05-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1941)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1946-05-26 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 65-99 mg/dL | Normal | S |
| 1946-05-26 | Left ventricular Ejection fraction | 62 | % | 52-72% | Normal | S |
| 1946-05-26 | Interventricular septum Thickness during diastole by US | 13 | mm | 6-10 mm | High | S |
| 1946-05-26 | Left ventricular Myocardial mass/Body surface area [Mass/Area] by US 2D | 118 | g/m2 | 49-115 g/m2 | High | S |
| 1946-05-26 | Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area | 36 | mL/m2 | 16-34 mL/m² | High | S |
Vital signs recorded on 1946-05-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 148/92 mmHg, pulse 74 |
| Cardiovascular | Regular rhythm; sustained apex beat; fourth heart sound; no murmur at rest or with Valsalva; no edema |
| Respiratory | Clear |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented work as a referee; superseded at the consultation when stress testing showed no ischemia and the symptom was attributed to hypertensive heart disease. |
| Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to follow | resolved | confirmed | I10 | S — Synthetic diagnosis at intake; reclassified as hypertensive heart disease after the echocardiogram at the consultation. |
| Hypertensive heart disease without heart failure: concentric left ventricular hypertrophy (septum 13 mm, mass index 118 g/m2) with normal ejection fraction, grade 1 diastolic dysfunction, a mildly enlarged left atrium and an exaggerated blood pressure rise on exercise; no features of hypertrophic cardiomyopathy | active | confirmed | I11.9 | S — Synthetic diagnosis made at the cardiology consultation; not a claim about his real heart. |
| Coronary atherosclerosis found by coronary calcium scoring (Agatston score 186, about the 80th percentile for his age and sex), without angina and with no inducible ischemia on exercise stress echocardiography | active | confirmed | I25.10 | S — Synthetic diagnosis made at the cardiology consultation; not a retrospective diagnosis of the cause of his death, which is disputed. |
| Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetes | active | confirmed | E78.00 | S — Synthetic diagnosis at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 148/92 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Seven-day average 146/92 mmHg; above the target of 130/80 |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Completed today | Two weeks after starting losartan-hydrochlorothiazide: sodium 139, potassium 4.0 mmol/L, creatinine 1.04 mg/dL, eGFR 87 |
| Laboratory | Urine albumin-to-creatinine ratio | At diagnosis, then yearly | Up to date | 22 mg/g at intake, normal |
| Laboratory | HbA1c | At diagnosis, then yearly | Up to date | 5.5% at intake |
| Laboratory | ALT before a statin | Once before starting a statin | Up to date | 24 U/L at intake |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | LDL 160 mg/dL at intake; recheck eight to twelve weeks after today's start |
| Imaging | 12-lead ECG | At diagnosis; then as clinically indicated | Up to date | Intake ECG: left ventricular hypertrophy by voltage, QTc 418 ms |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Completed today | Ejection fraction 62%, septum 13 mm, mass index 118 g/m2, left atrial volume index 36 mL/m2; no outflow obstruction |
| Imaging | Stress testing or coronary imaging | For new or changed exertional symptoms; not for routine surveillance | Completed today | Exercise stress echocardiogram for exertional symptoms: no inducible ischemia; coronary calcium score 186 |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | No chest tightness on undercard nights |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 74.4 kg, BMI 27.3; walking more |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | Takes the tablet each morning; no lightheadedness or cough |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Undercards only until home blood pressure is below 140/90; plan given in writing |
| Self-management | Sick-day rules | When starting an ARB or diuretic | Completed today | Hold the tablet on a day of vomiting, diarrhea or inability to drink, and call |
| Medication safety | Aspirin decision | When risk changes | Deferred | Not started while blood pressure is uncontrolled; to be revisited once it is controlled |
| Referral | Cardiology consultation | At intake | Completed today | Seen by Dr. Achebe-Lindqvist today |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (2021); 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026); 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026)
Follow-up: Home readings weekly by phone. Seven-week review at the end of June with a basic metabolic panel; lipid panel at eight to twelve weeks. Next scheduled visit 1946-06-30: seven-week review: home blood pressure, the first weeks back at full cards, symptoms, and a dose increase. [S]